摘要
239例急性心肌梗塞(AMI)患者接受溶栓治疗,其中采用日本尿激酶(UK)96万U35例,150万U55例;国产UK96万U15例,150万U53例;德国链激酶(SK)150万U66例;国产重组链激酶(rSK)150万U15例。对不同剂量及不同溶栓剂的疗效与安全性进行对比分析发现:1992年前国产UK96万U比日本进口UK96万U血管再通率低(20.0%vs51.4%P<0.01)。1992年后国产UK剂量增至150万U,血管再通率显著提高(56.6%vs20.0%P<0.01),与进口UK150万U的疗效与安全性相近(P>0.05);国产rSK150万U与进口SK150万U的血管再通率相似(73.3%vs65.2%P>0.05);且比国产UK150万U的血管再通率明显提高(73.3%vs56.6%P<0.05),虽然rSK轻度出血高于UK(26.7%vs9.4%P<0.01),偶有低血压发生,但不影响疗效。国产rSK与UK比进口SK和UK价格低2~4倍。因此认为,国产rSK和UK是较为有效、安全、价廉且适合我国国情的溶栓药物。
Two hundred and thirty nine patients with acute myocardial infarction(AMI)were treated with different thrombolytic agents and doses.Among them,35 cases received Japanese UK 960,000 U(groupⅠ);55 cases,Japanese UK 1.5 million U(groupⅡ);15 cases,Chinese UK 960,000 U produced before 1992(groupⅢ);53 cases,Chinese UK 1.5 million U produced after 1992(groupⅣ);66 cases,German SK 1.5 million U(groupⅤ);15 cases,Chinese rSK 1.5 million U(groupⅥ).The results showed that the reperfusion rate was significantly lower(20.0%vs 51.4%,P<0.01)and the mortality rate within 5 weeks was significantly higher(33.3%vs 11.4%,P<0.01)in groupⅢthan in groupⅠ.The reperfusion rate was significantly increased(56.6%vs 20.0%,P<0.01)in groupⅣthan in groupⅢand the efficacy and safety of groupⅣwere similar to groupⅡ(the reperfusion rates were 56.6%vs 61.8%,P>0.05,the incidence of mild bleeding was 9.4%vs 10.9%,P>0.05).The efficacy and safety of groupⅥwere also similar to groupⅤ(the reperfusion rates were 73.3%vs 65.2%,P>0.05;the incidences of mild bleeding were 26.7%vs 18.7%,P>0.05,and hypotension,6.7%vs 15.2%,P>0.05).The reperfusion rate was significantly higher(73.3%vs 55.6%,P<0.05)in Chinese rSK 1.5 milllion U group than that of Chinese UK 1.5 million U group,though mild hemorrhage and hypotension were more common in the former,they were not severe and did not affect the treatment.The prices of Chinese rSK and UK were two to four times lower than those of imported SK and UK.In conclusion,both Chinese rSK(1.5 million U)and UK(1.5 million U)were effective and safe thrombolytic agents for AMI and could be afforded by most patients in our country.
作者
丁文惠
张钧华
胡大一
邵耕
张玉华
刘梅林
韩改仙
袁德芹
汪丽蕙
Ding Wenhui;Zhang Junhu;Hu Dayi(Cardwruscular Depariment,First Teachmng Hosputal,Beijing Medacal University,Beijing 100034)
出处
《中华心血管病杂志》
CAS
CSCD
北大核心
1997年第4期277-279,共3页
Chinese Journal of Cardiology
关键词
心肌梗塞
溶栓治疗
尿激酶
链激酶
剂量
myocardial infarction
thrombolytsis
urokinase
streptokinase
recombinant streptokinase
